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First Prince de Bénévent (1)
Management of patients presenting with out-of-hospital
cardiac arrest is a perennially vexing problem because no
categorical predictors of neurological recovery exist. Predict-
ing the extent of brain damage permits more sensible
management efforts. Adding to the complexity of clinical
decision making by both family and medical staff is a stew of
ethical, economic, and emotional factors admixed with legal
issues. Almost 80% of patients with return of spontaneous
circulation after cardiopulmonary resuscitation remain un-
conscious for variable lengths of time (2). Of those, approx-
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imately 20% will enter a vegetative state (3), a condition
most patients sensibly prefer to avoid. This management
conundrum is amplified by anecdotal stories of dramatic and
unexpected recovery after prolonged unresponsiveness
wherein patients supposedly arise Lazarus-like from “coma
to consciousness” and by reporting a subtle and confusing
spectrum of consciousness (4). Lay media frequently omit or
minimize potentially ruinous social and financial aspects of
management: cost estimates for the care of severely brain-
damaged survivors run in billions of dollars annually includ-
ing extended hospital stays and rehabilitation (5). Not
surprisingly, as applied by the friends and family of individ-
ual patients, societal concerns such as resource utilization
and economic “best practice” are often irrelevant or frankly
offensive topics of discussion. Since the advent of cardio-
pulmonary resuscitation and its widespread out-of-hospital
adoption, many more patients survive to hospital admission,
prompting the question “Now what?”
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relevant to the contents of this paper to disclose.Clearly, prospects for meaningful recovery are enhanced
after a witnessed event in a young patient given prompt and
appropriate resuscitation who demonstrates signs of wake-
fulness on or within a short time of hospital admission.
Despite the attractiveness of the history, when available, it is
often unreliable, sometimes contradictory, frequently con-
founding and sometimes misleading. Given all this, it would
be extremely useful to have some sort of objective standard
for predicting functional recovery that would divide patients
in a binary fashion (“will recover completely” vs. “dismal
prognosis”) or at least assign them along a functional
recovery continuum extending from a temporary “scram-
bling” of consciousness to severe brain damage. It would be
even better if a determination of full recovery could be made
within the first 24 h of hospital admission. Right now, there
is no such measure.
In this issue of the Journal, Einav et al. (6) evaluate
serum-100B (S100B) and neuron-specific enolase (NSE) sam-
pled at intervals beginning on day 0 (representing initial
evaluation in the emergency department), extending through
the third day of hospitalization in combination with clinical
information to predict neurological recovery from out-of-
hospital cardiac arrest. The authors contend that functional
recovery in patients experiencing out-of-hospital cardiac
arrest within “ethically acceptable safety margins” can be
predicted thusly.
Physical examination has been used to predict outcome
in comatose survivors of cardiac arrest: it is inexpensive,
easy, and traditionally valued. Booth et al. (5) performed
a MEDLINE search extending from 1966 to 2003 to
determine examination precision and accuracy for pre-
dicting outcomes. Five findings, all of which are part of a
routine evaluation, were found to strongly predict death
or poor neurological outcome at 24 h: absence of corneal
reflexes; pupillary responses; withdrawal response to pain;
no motor response on admission and none at 72 h. The
most useful signs occur at 24 h after cardiac arrest, but
they caution that prognosis should not be rendered by
clinical examination alone; something else is necessary,
especially when induced hypothermia and sedation are
considered.
S100B is secreted by an astrocyte subtype and by
NG2-expressing cells. It is detectable in the periphery by
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ing the acute phase of central nervous system injury. Its
clinical utility in the evaluation of hypoxic and other
central nervous system damage results from its ability to
cross the blood-brain barrier and appear in the serum
where it can be detected and quantified. S100B levels
reportedly increase before changes in intracerebral pres-
sure, neuroimaging, and physical examination are evi-
dent. The major advantage of S100B is that abnormal
levels provide a sensitive measure for detecting central
nervous injury before gross changes develop.
NSE, a protein contained in neurons and neuroendo-
crine cells, is released in anoxic brain damage. The level
of NSE presumably correlates with the extent of injury
and thus with prognosis. Plasma concentrations of NSE
have been studied in out-of-hospital cardiac arrest (7–15). In the
aggregate, data suggest a direct correlation between
serum NSE levels and outcome categories. For example,
Reisinger et al. (15) reported a cohort study of 177
patients with NSE measured on admission and 1 to 3
days afterward. Levels generally peaked 2 to 3 days
post-admission. Poor outcome (death or persistent coma)
occurred in all 37 patients with a peak NSE level of
0.80 ng/ml (specificity 100%); NSE levels were lower in
22 additional cases (sensitivity 63%).
What does the study by Einav et al. (6) add to all this?
Serial NSE and S100B measurements and the reasonably
large sample size are strengths of the study as is the study
endpoint (good vs. bad outcomes); in fact, this endpoint
is clinically critical. Of 195 eligible patients, only 43
(22%) survived to hospital discharge, 26 (13%) of whom
had a good outcome as defined by the Cerebral Perfor-
mance Scale (CPC) (16). The levels of both S100B and
NSE were significantly lower in those with a CPC score
of 1 to 2 than those with poor outcomes (CPC score 3 to
5). Their model found that “the level of NSE became
non-significant and the model retained only three signif-
icant variables: age, VT/VF and the level of S100B at
admission.” But S100B measurements obtained on day 0
added only 5% predictive value to clinical factors with
n overall accuracy of 93%. Evidently NSE measure-
ments can be jettisoned when S100B, age, and ventricular
tachycardia/ventricular fibrillation (VT/VF) are ac-
counted for, although S100B contributes a small addi-
tional improvement (odds: 2.14; p  0.03).
Einav et al. (6) omit various “tried and true” physical
findings with demonstrated prognostic significance (5). So
it is not clear what influence, if any, incorporation of corneal
and pupillary reflexes and others might have on their model
and what effect the relatively high mortality rate in their
population might have produced on their results. Neuro-
imaging and other testing were not reported, so their
influence on the model is also unknown. The authors
state that “[a]lthough biomarker data independently con-
tributed an ostensibly modest 5.2% to the AUC, they
substantially reduced the probability of misclassificationerror compared with that based solely on clinical criteria.”
One might therefore presume that age 66 years and
VT/VF are sufficient for rendering a clinical decision.
Everyone involved in post-resuscitation management
wants to know 2 things: when to cease supportive efforts and
what the prospects are for a good recovery given continued
care. The paper does not directly address exactly how
biomarkers would affect the decision. Clearly age 66 years
(odds: 10 univariate and 6 multivariate) and VT/VF (odds:
17 univariate and 11 multivariate) are the salient predictive
factors, and they are available at admission. On arrival or
during the first day, S100B is influential. The crux issue is
and remains society’s (and physicians’) priorities regarding
both when and how the decision is made to stop resuscita-
tion. It is only reasonable to conclude, as the authors do,
that “[p]arallel to searching for the infallible brain bio-
marker, policy makers should determine the level of risk of
misclassification acceptable to their society within this
clinical setting.”
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